Allergan's 'double-chin' treatment gets positive opinion in Sweden

Allergan PLC said Friday belkyra, a treatment for submental fullness, or double chins, received a "positive opinion" from the Swedish Medical Products Agency. The Ireland-based drugmaker said it belkyra will be the first prescription treatment for the treatment of double chins in adults, when it has a psychological impact on the patient. Belkyra is currently licensed in Canada and in the U.S. as Kybella. "We look forward to our continued work with the 20 EU member states, Norway and Iceland to secure marketing authorizations to make this important new treatment option available to customers and patients," said Chief R&D Officer David Nicholson. The stock, which was still inactive in premarket trade, has tumbled 26% year to date, while the SPDR Health Care Select Sector ETF has lost 0.5% and the S&P 500 has gained 2.7%.

Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.